Loading…
Atomix LLC was cited for marketing unapproved new drugs, specifically selective androgen receptor modulators (SARMs) including MK-2866 (Ostarine) and RAD-140 (Testolone), in violation of sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act. Despite labeling claims of "research use only" and "not for human consumption," FDA determined the products were intended for human use based on website marketing and product labeling that suggested they could affect body structure and function. The company promoted these products directly to consumers through its website and social media accounts (Instagram and Facebook), creating a direct sales channel. FDA identified serious safety concerns associated with SARMs, including documented cases of life-threatening liver toxicity and potential increased risk of heart attack and stroke.